StockWaves
  • Home
  • Global Markets
    Global MarketsShow More
    This 26-year-old’s blue-collar enterprise brings in .3 million a 12 months
    This 26-year-old’s blue-collar enterprise brings in $1.3 million a 12 months
    9 Min Read
    Barclays upgrades GN Retailer Nord inventory to Obese on earnings inflection
    Barclays upgrades GN Retailer Nord inventory to Obese on earnings inflection
    0 Min Read
    3 distinctive funding trusts that would enhance the returns of a Shares and Shares ISA
    3 distinctive funding trusts that would enhance the returns of a Shares and Shares ISA
    4 Min Read
    China shares lag broad Asia rebound,Fed price reduce hopes and Nvidia-Chin
    China shares lag broad Asia rebound,Fed price reduce hopes and Nvidia-Chin
    0 Min Read
    Chinese language corporations chase Africa’s shoppers as useful resource investments plunge 40%
    Chinese language corporations chase Africa’s shoppers as useful resource investments plunge 40%
    9 Min Read
  • Investment Strategies
    Investment StrategiesShow More
    Lloyds Metals & Vitality Ltd – Constructing India’s Subsequent Mining-to-Metals PowerhouseInsights
    Lloyds Metals & Vitality Ltd – Constructing India’s Subsequent Mining-to-Metals PowerhouseInsights
    9 Min Read
    Traders misplaced over 50% good points by lacking the 'finest 3 months'
    Traders misplaced over 50% good points by lacking the 'finest 3 months'
    0 Min Read
    Don't play the ready sport
    Don't play the ready sport
    0 Min Read
    PPFAS plans IPO in 5 years, entry into NPS
    PPFAS plans IPO in 5 years, entry into NPS
    0 Min Read
    Comparable valuations, reverse outcomes
    Comparable valuations, reverse outcomes
    0 Min Read
  • Market Analysis
    Market AnalysisShow More
    Is It Truly Value Rs. 3,000?
    Is It Truly Value Rs. 3,000?
    11 Min Read
    Inventory to purchase briefly time period: Axis Securities recommends this PSU inventory as its ‘Decide of the Week’
    Inventory to purchase briefly time period: Axis Securities recommends this PSU inventory as its ‘Decide of the Week’
    6 Min Read
    YES Financial institution Inventory in Consolidation: A Lengthy-Time period Investor’s Perspective
    YES Financial institution Inventory in Consolidation: A Lengthy-Time period Investor’s Perspective
    10 Min Read
    Nifty, Sensex open flat amid optimism of touching contemporary highs: Consultants
    Nifty, Sensex open flat amid optimism of touching contemporary highs: Consultants
    4 Min Read
    Is that this flexi-cap fund getting too huge to shine
    Is that this flexi-cap fund getting too huge to shine
    0 Min Read
  • Trading
    TradingShow More
    Scott Bessent Says If ‘Radical Left’ Once more Shuts Down Authorities In January, GOP Ought to ‘Instantly Finish’ The Filibuster
    Scott Bessent Says If ‘Radical Left’ Once more Shuts Down Authorities In January, GOP Ought to ‘Instantly Finish’ The Filibuster
    3 Min Read
    Mamdani Says He ‘Continues To Imagine’ Every little thing He’d Mentioned Earlier About Trump Regardless of ‘Very Productive’ Assembly
    Mamdani Says He ‘Continues To Imagine’ Every little thing He’d Mentioned Earlier About Trump Regardless of ‘Very Productive’ Assembly
    3 Min Read
    Scott Bessent Says Individuals Set For ‘Lowest Price’ Thanksgiving Dinner In 4 Years After Being ‘Traumatized’ By Biden-Period Costs
    Scott Bessent Says Individuals Set For ‘Lowest Price’ Thanksgiving Dinner In 4 Years After Being ‘Traumatized’ By Biden-Period Costs
    3 Min Read
    The Insider Report: Put together for the Subsequent Dip Shopping for Alternative – Daqo New Power (NYSE:DQ), Dianthus Therapeutics (NASDAQ:DNTH)
    The Insider Report: Put together for the Subsequent Dip Shopping for Alternative – Daqo New Power (NYSE:DQ), Dianthus Therapeutics (NASDAQ:DNTH)
    21 Min Read
    Elon Musk’s Ex-Spouse Shared Insights Into Their Tumultuous Marriage – Tesla (NASDAQ:TSLA)
    Elon Musk’s Ex-Spouse Shared Insights Into Their Tumultuous Marriage – Tesla (NASDAQ:TSLA)
    3 Min Read
Reading: An Interview with Dr. Divneet Kaur, CEO of Dermabay
Share
Font ResizerAa
StockWavesStockWaves
  • Home
  • Global Markets
  • Investment Strategies
  • Market Analysis
  • Trading
Search
  • Home
  • Global Markets
  • Investment Strategies
  • Market Analysis
  • Trading
Follow US
2024 © StockWaves.in. All Rights Reserved.
StockWaves > Business > An Interview with Dr. Divneet Kaur, CEO of Dermabay
Business

An Interview with Dr. Divneet Kaur, CEO of Dermabay

StockWaves By StockWaves Last updated: July 16, 2025 7 Min Read
An Interview with Dr. Divneet Kaur, CEO of Dermabay
SHARE


Contents
An Interview with Dr. Divneet Kaur, a Pharmaceutical Scientist, Co-Founder & CEO of Dermabay, a science-first, formulation-led Indian skincare modelAre you able to share your journey into the pharmaceutical business and what impressed you to co-found Dermabay?What distinctive challenges did you face whereas establishing Dermabay, and the way did you overcome them?Are you able to focus on the analysis and improvement course of behind Dermabay’s merchandise?How does Dermabay differentiate itself from different firms within the pharmaceutical and skincare sectors?How do you guarantee the protection and efficacy of your merchandise throughout the improvement course of?How do you method collaboration with different scientists and researchers within the area?What recommendation would you give to aspiring entrepreneurs within the pharmaceutical business?

An Interview with Dr. Divneet Kaur, a Pharmaceutical Scientist, Co-Founder & CEO of Dermabay, a science-first, formulation-led Indian skincare model

In an unique interview, we converse with Dr. Divneet Kaur, Co-Founder & CEO of Dermabay, a science-first, formulation-led Indian skincare model. Discover her journey and imaginative and prescient for revolutionary magnificence.

Are you able to share your journey into the pharmaceutical business and what impressed you to co-found Dermabay?

Dr. Divneet Kaur: I entered pharmaceutical sciences to specialise in drug supply programs and transdermal peptide applied sciences. The most important subject I noticed throughout my time working throughout analysis labs and mentoring college students was the growing disconnect between scientific breakthroughs and client accessibility of skincare merchandise.

I skilled many requests from folks in my setting about their skincare merchandise failing to ship regardless of their costly pricing and worldwide origins. That was my turning level.

The scientific group in India possessed all mandatory data however did not translate analysis into sensible skincare options. This discovery remodeled into the inspiration that created Dermabay.

What distinctive challenges did you face whereas establishing Dermabay, and the way did you overcome them?

Dr. Divneet Kaur: The most important impediment we confronted was staying away from widespread practices of latest skincare manufacturers which concerned white-labeling or blindly following the traits.

Our firm made an intentional resolution to supply each components internally by conducting thorough testing and taking full accountability for our provide chain administration.

We pursued this method to make sure formulation integrity on the expense of prolonged manufacturing timelines and elevated prices.

The primary problem concerned educating customers in regards to the significance of ingredient transparency and stability alongside bioavailability. We achieved this by telling tales primarily based on scientific details as a substitute of utilizing promotional gimmicks.

Are you able to focus on the analysis and improvement course of behind Dermabay’s merchandise?

Dr. Divneet Kaur: Each product begins with figuring out its scientific goal which incorporates understanding the problem-solution and the actives that present effectiveness below Indian situations.

Our R&D group comprising of pharmaceutical marvels and dermatology consultants begins by growing prototypes which mix steady molecules with optimized absorption patterns and organic compatibility.

Our group then conducts successive rounds of inner product testing which results in modifications primarily based on prompt suggestions. The lengthy deliberate improvement course of allows us to construct skincare merchandise that ship efficiency slightly than traits.

How does Dermabay differentiate itself from different firms within the pharmaceutical and skincare sectors?

Dr. Divneet Kaur: Dermabay connects pharmaceutical-grade formulation to skin-first empathy. Our firm focuses on utilizing imported energetic elements along with advertising tales for skincare merchandise as a result of we think about medical perform alongside indigenous formulation design and long-term pores and skin compatibility.

We don’t promote routines—they’re remodeled into tangible outcomes. Our dedication to scientific excellence and sincere communication about pores and skin well being has remained fixed from our humble beginnings to working with main dermatologists in India.

Our genuine model identification mixed with our full management over formulation mental property makes us distinctive out there.

How do you guarantee the protection and efficacy of your merchandise throughout the improvement course of?

Dr. Divneet Kaur: Our formulations obtain the identical degree of consideration as drug molecules throughout the improvement course of. We prioritize security and efficacy collectively by following these important ideas:

  • Ingredient sourcing from verified suppliers
  • Energetic focus primarily based on medical data
  • Stability testing in assorted Indian temperatures and humidity ranges
  • Patch testing for sensitivity and irritation
  • Compliance with regulatory and dermatological requirements

We check new merchandise on precise customers in managed settings earlier than releasing them into market. All merchandise have to show their efficiency on actual Indian pores and skin by means of knowledge proof and safe confidence earlier than they are often launched to the general public.

How do you method collaboration with different scientists and researchers within the area?

Dr. Divneet Kaur: We contemplate collaboration to be an important obligation as a substitute of an elective selection. Our firm conducts common consultations with dermatologists together with beauty chemists and pharmacologists to enhance our formulation strategies.

Our product prototypes obtain steady suggestions from exterior researchers all through the event course of.

I preserve common contact with educational establishments whereas mentoring younger researchers as a result of I consider scientists ought to work collectively as a substitute of competing towards one another.

What recommendation would you give to aspiring entrepreneurs within the pharmaceutical business?

Dr. Divneet Kaur: Construct for depth, not velocity. Pharmaceutical science requires scientists to show persistence and precision and to keep up a humble method to their work.

Actual-world impact takes priority over fast market entry. Your group ought to embody consultants who each perceive scientific ideas and client wants.

The method of innovation turns into profitable by means of your capability to simplify advanced concepts into easy-to-understand ideas and develop options that deal with real-world issues.

Your credibility capabilities as your monetary useful resource so you could defend it towards any potential threats.

Dr. Kaur’s insights illuminate Dermabay’s dedication to efficient, evidence-based skincare. Her imaginative and prescient empowers customers with scientifically crafted merchandise, shaping the way forward for Indian magnificence.



Are you an
Entrepreneur or Startup?


Do you’ve a Success Story to Share?

SugerMint wish to share your success story.
We cowl entrepreneur Tales, Startup Information, Ladies entrepreneur tales, and Startup tales


Discover Success story of Indian entrepreneurs & startups at SugerMint. Comply with us on Twitter, Instagram, Fb, LinkedIn



Sign Up For Daily Newsletter

Be keep up! Get the latest breaking news delivered straight to your inbox.

By signing up, you agree to our Terms of Use and acknowledge the data practices in our Privacy Policy. You may unsubscribe at any time.
Share This Article
Facebook Twitter Copy Link Print
Previous Article Asian shares decline: Asian shares decline as Fed price lower bets wane Asian shares decline: Asian shares decline as Fed price lower bets wane
Next Article Mike Johnson Breaks Ranks With Trump On The ‘Very Delicate Topic’ Of Epstein: ‘I am For Transparency’ – Tesla (NASDAQ:TSLA) Mike Johnson Breaks Ranks With Trump On The ‘Very Delicate Topic’ Of Epstein: ‘I am For Transparency’ – Tesla (NASDAQ:TSLA)
Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

FacebookLike
TwitterFollow
PinterestPin
InstagramFollow

Subscribe Now

Subscribe to our newsletter to get our newest articles instantly!

Most Popular
This 26-year-old’s blue-collar enterprise brings in .3 million a 12 months
This 26-year-old’s blue-collar enterprise brings in $1.3 million a 12 months
November 24, 2025
Pibit.AI raises M from Stellaris Enterprise Companions to construct trusted AI for the insurance coverage {industry}
Pibit.AI raises $7M from Stellaris Enterprise Companions to construct trusted AI for the insurance coverage {industry}
November 24, 2025
RVNL Wins Rs 181 Crore NE Railway Order; Shares Commerce Flat
RVNL Wins Rs 181 Crore NE Railway Order; Shares Commerce Flat
November 24, 2025
Barclays upgrades GN Retailer Nord inventory to Obese on earnings inflection
Barclays upgrades GN Retailer Nord inventory to Obese on earnings inflection
November 24, 2025
Is It Truly Value Rs. 3,000?
Is It Truly Value Rs. 3,000?
November 24, 2025

You Might Also Like

‘Pani chahiye, pani?’ BJP MP PC Mohan shares photos of Pakistan’s Chenab river drying up after Indus treaty suspension
Business

‘Pani chahiye, pani?’ BJP MP PC Mohan shares photos of Pakistan’s Chenab river drying up after Indus treaty suspension

3 Min Read
NAM India Q3 Outcomes: Revenue up 4% to Rs 295 crore
Business

NAM India Q3 Outcomes: Revenue up 4% to Rs 295 crore

6 Min Read
Is Your Companion Your Very best Quantity Match?
Business

Is Your Companion Your Very best Quantity Match?

9 Min Read
Choose money burning case: MPs submit notices for Justice Yashwant Varma’s elimination to LS Speaker, RS Chairman
Business

Choose money burning case: MPs submit notices for Justice Yashwant Varma’s elimination to LS Speaker, RS Chairman

3 Min Read

Always Stay Up to Date

Subscribe to our newsletter to get our newest articles instantly!

StockWaves

We provide tips, tricks, and advice for improving websites and doing better search.

Latest News

  • About Us
  • Contact Us
  • Privacy Policy
  • Terms Of Service

Resouce

  • Blockchain
  • Business
  • Economics
  • Financial News
  • Global Markets
  • Investment Strategies
  • Market Analysis
  • Trading

Trending

This 26-year-old’s blue-collar enterprise brings in $1.3 million a 12 months
Pibit.AI raises $7M from Stellaris Enterprise Companions to construct trusted AI for the insurance coverage {industry}
RVNL Wins Rs 181 Crore NE Railway Order; Shares Commerce Flat

2024 © StockWaves.in. All Rights Reserved.

Welcome Back!

Sign in to your account

Not a member? Sign Up